OVG led the UK paediatric clinical trials of vaccines against the H1N1 pandemic virus in Autumn 2009 enrolling 943 children in five weeks, and enabling immunisation recommendations by the Department of Health for three million children under five years of age and informing global policy. We had previously evaluated H5N1 vaccines, showing poor responses to standard non-adjuvanted vaccines, which informed development in the 2009 pandemic. We led an expedited phase II clinical trial of an adenovirus/MVA Ebola vaccine Ebola (contributing to approval by the European Medicines Agency in 2020) in response to the huge 2013 West African outbreak.

This is one of only two licensed Ebola vaccines and was recently deployed for outbreak control in the Democratic Republic of Congo (DRC). During the recent filovirus outbreaks in 2022-2023 in Equatorial Guinea, Tanzania and Uganda, two vaccines designed and tested by OVG (Lambe) were selected by the WHO Technical Advisory Group (TAG CVP) for inclusion in ring vaccination trials. In just 60 days, the Serum Institute of India manufactured approx. 400,000 doses with 40,000 doses deployed to Uganda during the outbreak.